Yonsei Med J.  2014 Jul;55(4):960-966. 10.3349/ymj.2014.55.4.960.

Correlation between Soluble Triggering Receptor Expressed on Myeloid Cells-1 and Endoscopic Activity in Intestinal Behcet's Disease

• Lee HJ
• Shin HS
• Jang HW
• Kim SW
• Park SJ
• Hong SP
• Kim TI
• Kim WH
• Cheon JH

• KMID: 2130820
• DOI: http://doi.org/10.3349/ymj.2014.55.4.960

Abstract

PURPOSE
The serum levels of soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) have recently been shown to be correlated highly with disease activity in patients with intestinal Behcet's disease (BD). However, it remains unclear whether sTREM-1 levels reflect endoscopic activity in intestinal BD. This study aimed to evaluate the correlation of sTREM-1 levels with endoscopic activity in intestinal BD.
MATERIALS AND METHODS
A total of 84 patients with intestinal BD were enrolled. Endoscopic activity was compared with sTREM-1 levels as well as other laboratory findings, including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP).
RESULTS
sTREM-1 levels were significantly increased in intestinal BD patients compared with controls (37.98+/-27.09 pg/mL vs. 16.65+/-7.76 pg/mL, p=0.002), however, there was no difference between endoscopically quiescent and active diseases (43.53+/-24.95 pg/mL vs. 42.22+/-32.68 pg/mL, p=0.819). Moreover, serum sTREM-1 levels did not differ in terms of number, shape, depth, size, margin, or type of ulcer in patients with intestinal BD. However, mean ESR and CRP levels in patients with active disease were significantly higher than those in patients with quiescent disease (p=0.001, p<0.001, respectively). In addition, endoscopic activity scores for intestinal BD were correlated significantly with both CRP levels (gamma=0.329) and ESR (gamma=0.298), but not with sTREM-1 levels (gamma=0.166).
CONCLUSION
Unlike CRP levels and ESR, serum sTREM-1 levels were not correlated with endoscopic activity in patients with intestinal BD.

Keyword

C-reactive protein; endoscopic activity; erythrocyte sedimentation rate; intestinal Behcet's disease; triggering receptor expressed on myeloid cells-1

MeSH Terms

Adult
Behcet Syndrome/*blood/*pathology
Biological Markers/blood
Blood Sedimentation
C-Reactive Protein/metabolism
Female
Humans
Intestinal Diseases/*blood/*pathology
Male
Membrane Glycoproteins/*blood
Receptors, Immunologic/*blood
Biological Markers
C-Reactive Protein
Membrane Glycoproteins
Receptors, Immunologic

Figure

• 

  Fig. 1 Serum sTREM-1 levels were significantly higher in patients with intestinal BD than in controls. BD, Behçet's disease; sTREM-1, soluble triggering receptor expressed on myeloid cells-1.

Reference

1. Ebert EC. Gastrointestinal manifestations of Behçet's disease. Dig Dis Sci. 2009; 54:201–207.

2. Allez M, Lémann M. Role of endoscopy in predicting the disease course in inflammatory bowel disease. World J Gastroenterol. 2010; 16:2626–2632.

3. Cheon JH, Kim WH. Recent advances of endoscopy in inflammatory bowel diseases. Gut Liver. 2007; 1:118–125.

4. Frøslie KF, Jahnsen J, Moum BA, Vatn MH. IBSEN Group. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. 2007; 133:412–422.

5. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012; 61:1619–1635.

6. Vermeire S, Van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006; 55:426–431.

7. Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther. 2007; 25:247–255.

8. Grigg EL, Kane S, Katz S. Mimicry and deception in inflammatory bowel disease and intestinal behçet disease. Gastroenterol Hepatol (N Y). 2012; 8:103–112.

9. Cheon JH, Han DS, Park JY, Ye BD, Jung SA, Park YS, et al. Development, validation, and responsiveness of a novel disease activity index for intestinal Behçet's disease. Inflamm Bowel Dis. 2011; 17:605–613.

10. Lee HJ, Kim YN, Jang HW, Jeon HH, Jung ES, Park SJ, et al. Correlations between endoscopic and clinical disease activity indices in intestinal Behcet's disease. World J Gastroenterol. 2012; 18:5771–5778.

11. Bouchon A, Dietrich J, Colonna M. Cutting edge: inflammatory responses can be triggered by TREM-1, a novel receptor expressed on neutrophils and monocytes. J Immunol. 2000; 164:4991–4995.

12. Gibot S, Cravoisy A, Levy B, Bene MC, Faure G, Bollaert PE. Soluble triggering receptor expressed on myeloid cells and the diagnosis of pneumonia. N Engl J Med. 2004; 350:451–458.

13. Gibot S, Le Renard PE, Bollaert PE, Kolopp-Sarda MN, Béné MC, Faure GC, et al. Surface triggering receptor expressed on myeloid cells 1 expression patterns in septic shock. Intensive Care Med. 2005; 31:594–597.

14. Collins CE, La DT, Yang HT, Massin F, Gibot S, Faure G, et al. Elevated synovial expression of triggering receptor expressed on myeloid cells 1 in patients with septic arthritis or rheumatoid arthritis. Ann Rheum Dis. 2009; 68:1768–1774.

15. Schenk M, Bouchon A, Seibold F, Mueller C. TREM-1--expressing intestinal macrophages crucially amplify chronic inflammation in experimental colitis and inflammatory bowel diseases. J Clin Invest. 2007; 117:3097–3106.

16. Tzivras M, Koussoulas V, Giamarellos-Bourboulis EJ, Tzivras D, Tsaganos T, Koutoukas P, et al. Role of soluble triggering receptor expressed on myeloid cells in inflammatory bowel disease. World J Gastroenterol. 2006; 12:3416–3419.

17. Park JJ, Cheon JH, Kim BY, Kim DH, Kim ES, Kim TI, et al. Correlation of serum-soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease. Dig Dis Sci. 2009; 54:1525–1531.

18. Jung YS, Park JJ, Kim SW, Hong SP, Kim TI, Kim WH, et al. Correlation between soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) expression and endoscopic activity in inflammatory bowel diseases. Dig Liver Dis. 2012; 44:897–903.

19. Jung YS, Kim SW, Yoon JY, Lee JH, Jeon SM, Hong SP, et al. Expression of a soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) correlates with clinical disease activity in intestinal Behcet's disease. Inflamm Bowel Dis. 2011; 17:2130–2137.

20. Cheon JH, Kim ES, Shin SJ, Kim TI, Lee KM, Kim SW, et al. Development and validation of novel diagnostic criteria for intestinal Behçet's disease in Korean patients with ileocolonic ulcers. Am J Gastroenterol. 2009; 104:2492–2499.

21. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005; 11:707–712.

22. Jung YS, Yoon JY, Lee JH, Jeon SM, Hong SP, Kim TI, et al. Prognostic factors and long-term clinical outcomes for surgical patients with intestinal Behcet's disease. Inflamm Bowel Dis. 2011; 17:1594–1602.

23. Choi CH, Kim TI, Kim BC, Shin SJ, Lee SK, Kim WH, et al. Anti-Saccharomyces cerevisiae antibody in intestinal Behçet's disease patients: relation to clinical course. Dis Colon Rectum. 2006; 49:1849–1859.

24. Saurer L, Rihs S, Birrer M, Saxer-Seculic N, Radsak M, Mueller C, et al. Elevated levels of serum-soluble triggering receptor expressed on myeloid cells-1 in patients with IBD do not correlate with intestinal TREM-1 mRNA expression and endoscopic disease activity. J Crohns Colitis. 2012; 6:913–923.

25. Billioud V, Gibot S, Massin F, Oussalah A, Chevaux JB, Williet N, et al. Plasma soluble triggering receptor expressed on myeloid cells-1 in Crohn's disease. Dig Liver Dis. 2012; 44:466–470.

26. Kasahara Y, Tanaka S, Nishino M, Umemura H, Shiraha S, Kuyama T. Intestinal involvement in Behçet's disease: review of 136 surgical cases in the Japanese literature. Dis Colon Rectum. 1981; 24:103–106.

27. Moon CM, Cheon JH, Shin JK, Jeon SM, Bok HJ, Lee JH, et al. Prediction of free bowel perforation in patients with intestinal Behçet's disease using clinical and colonoscopic findings. Dig Dis Sci. 2010; 55:2904–2911.

28. Ginsburg PM, Bayless TM. How can IBD be distinguished from IBS? Inflamm Bowel Dis. 2008; 14:Suppl 2. S152–S154.

29. Grundmann O, Yoon SL. Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners. J Gastroenterol Hepatol. 2010; 25:691–699.

30. Foell D, Wittkowski H, Ren Z, Turton J, Pang G, Daebritz J, et al. Phagocyte-specific S100 proteins are released from affected mucosa and promote immune responses during inflammatory bowel disease. J Pathol. 2008; 216:183–192.

31. Park JJ, Kim WH, Cheon JH. Outcome predictors for intestinal Behçet's disease. Yonsei Med J. 2013; 54:1084–1090.